Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 734

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 734
---
     -  
     - 
  
    State 
     -  
     - 
  
    Foreign 
     -  
     - 
  
    Current income tax expense 
     -  
     - 

    Deferred expense (benefit) 
     -  
     - 
  
    Federal 
     -  
     - 
  
    State 
     -  
     - 
  
    Foreign 
     -  
     - 
  
    Deferred income tax 
     -  
     - 
  
    Net deferred taxes 
    $-  
    $- 

A reconciliation of income tax benefit computed
using the federal statutory income tax rate to the Company’s tax expense is as follows:

    (in thousands, except percentage) 
    December 31,  2024  
    December 31,  2023 
  
    Federal tax benefit at statutory rate (21%) 
    $(8,837) 
    $(6,302)
  
    Stock-based compensation 
     1,297  
     1,143 
  
    State income tax benefit, net of federal tax effect 
     (320) 
     (222)
  
    Foreign tax differential 
     (482) 
     (241)
  
    Research credits 
     268  
     266 
  
    Other 
     2  
     3 
  
    Return to provision adjustment 
     2,052  
     335 
  
    Change in valuation allowance 
     6,020  
     5,018 
  
    Income tax benefit 
    $-  
    $- 

F-18

The principal components of deferred tax assets
and liabilities consist of the following at December 31, 2024 and 2023, respectively:

    (in thousands) 
    December 31,  2024  
    December 31,  2023 
  
    Deferred tax assets 

    Stock-based compensation 
    $2,142  
    $2,208 
  
    Research and development 
     4,716  
     2,900 
  
    Federal NOL carryforwards 
     8,686  
     6,849 
  
    State NOL carryforwards 
     1,923  
     1,685 
  
    Foreign N